Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for sequence
-0.54 (-0.36%)
After Hours: 145.60 -4.50 (-3.00%)
Jul 26, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 149.28 - 152.33
52 week 127.10 - 220.86
Open 150.00
Vol / Avg. 1.66M/1.21M
Mkt cap 22.08B
P/E 53.97
Div/yield     -
EPS 2.78
Shares 147.20M
Beta 0.89
Inst. own 97%
Jul 26, 2016
Q2 2016 Illumina Inc Earnings Call - Webcast
Jul 26, 2016
Q2 2016 Illumina Inc Earnings Release
Jun 15, 2016
Illumina Inc at William Blair Growth Stock Conference
Jun 8, 2016
Illumina Inc at Goldman Sachs Global Healthcare Conference
May 26, 2016
Illumina Inc Annual Shareholders Meeting (Estimated)
May 18, 2016
Illumina Inc Annual Shareholders Meeting
May 11, 2016
Illumina Inc at Bank of America Merrill Lynch Health Care Conference
May 3, 2016
Q1 2016 Illumina Inc Earnings Call - Webcast
May 3, 2016
Q1 2016 Illumina Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '16) 2016
Net profit margin 15.25% 20.61%
Operating margin 21.24% 27.61%
EBITD margin - 33.41%
Return on average assets 9.35% 13.02%
Return on average equity 18.72% 27.88%
Employees 4,600 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Officers and directors

Jay T. Flatley Executive Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Francis A. deSouza President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Marc A. Stapley Chief Financial Officer, Executive Vice President, Chief Administrative Officer
Age: 46
Bio & Compensation  - Reuters
Christian O. Henry Chief Commercial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Tristan B. Orpin Executive Vice President - Clinical Genomics
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Omead Ostadan Executive Vice President - Operations, Products and Strategy
Age: 44
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Paul L. Bianchi Senior Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters
Nicholas J. Naclerio Ph.D. Senior Vice President - Corporate and Venture Development
Age: 54
Bio & Compensation  - Reuters